<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7291183\results\search\disease\results.xml">
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="in collaboration with biotech companies have identified strategies to use" exact="viral" post="proteins as vaccine candidates for COVID-19. Although this looks"/>
  <result pre="a justified approach, but the problem is that in the" exact="absence of" post="animal studies, we can never predict the outcomes in"/>
  <result pre="to spread around the world. This virus is called â€˜severe" exact="acute" post="respiratory syndrome coronavirus 2â€™ (SARS-CoV-2) and the disease caused"/>
  <result pre="spread around the world. This virus is called â€˜severe acute" exact="respiratory" post="syndrome coronavirus 2â€™ (SARS-CoV-2) and the disease caused is"/>
  <result pre="around the world. This virus is called â€˜severe acute respiratory" exact="syndrome" post="coronavirus 2â€™ (SARS-CoV-2) and the disease caused is called"/>
  <result pre="called â€˜severe acute respiratory syndrome coronavirus 2â€™ (SARS-CoV-2) and the" exact="disease" post="caused is called â€˜coronavirus disease 2019â€™ (COVID-19). As of"/>
  <result pre="coronavirus 2â€™ (SARS-CoV-2) and the disease caused is called â€˜coronavirus" exact="disease" post="2019â€™ (COVID-19). As of 5 May 2020, a total"/>
  <result pre="â€˜coronavirus disease 2019â€™ (COVID-19). As of 5 May 2020, a" exact="total" post="of 3,517,345 confirmed clinical episodes of COVID-19 and 243,401"/>
  <result pre="worldwide (WHO 2020a). Most SARS-CoV-2-infected people experience mild to moderate" exact="respiratory" post="distress and generally recover without requiring any special treatment."/>
  <result pre="of age), and those with underlying medical complications like diabetes," exact="cardiovascular disease," post="chronic respiratory disease and cancer are more likely to"/>
  <result pre="and those with underlying medical complications like diabetes, cardiovascular disease," exact="chronic" post="respiratory disease and cancer are more likely to develop"/>
  <result pre="those with underlying medical complications like diabetes, cardiovascular disease, chronic" exact="respiratory" post="disease and cancer are more likely to develop serious"/>
  <result pre="with underlying medical complications like diabetes, cardiovascular disease, chronic respiratory" exact="disease" post="and cancer are more likely to develop serious symptoms"/>
  <result pre="medical complications like diabetes, cardiovascular disease, chronic respiratory disease and" exact="cancer" post="are more likely to develop serious symptoms like acute"/>
  <result pre="and cancer are more likely to develop serious symptoms like" exact="acute" post="respiratory disease and multiorgan failure, ultimately leading to death"/>
  <result pre="cancer are more likely to develop serious symptoms like acute" exact="respiratory" post="disease and multiorgan failure, ultimately leading to death (Lai"/>
  <result pre="are more likely to develop serious symptoms like acute respiratory" exact="disease" post="and multiorgan failure, ultimately leading to death (Lai et"/>
  <result pre="belongs to the same family as that of SARS (severe" exact="acute" post="respiratory syndrome) and MERS (Middle East respiratory syndrome) viruses"/>
  <result pre="to the same family as that of SARS (severe acute" exact="respiratory" post="syndrome) and MERS (Middle East respiratory syndrome) viruses that"/>
  <result pre="of SARS (severe acute respiratory syndrome) and MERS (Middle East" exact="respiratory" post="syndrome) viruses that were responsible for epidemics in 2003"/>
  <result pre="transmission rates from humans to humans is still ambiguous. For" exact="infection" post="into human cells, the receptor-binding domain of spike protein"/>
  <result pre="then cleaved by a protease, causing the fusion of the" exact="viral" post="envelope to the host cell membrane, completing the entry"/>
  <result pre="helps in effective cleavage by furin and proteases and determines" exact="viral" post="infectivity and host range (Andersen et al. 2020). Interestingly,"/>
  <result pre="range (Andersen et al. 2020). Interestingly, in case of the" exact="avian influenza" post="virus, the gain of this polybasic site in HA"/>
  <result pre="to be, for now, several folds higher (Rosenbaum 2020). The" exact="infection" post="has advanced to more than 210 countries and territories"/>
  <result pre="a global trial, called SOLIDARITY, to investigate whether this dangerous" exact="respiratory" post="disease could be treated with the available therapeutic aids"/>
  <result pre="global trial, called SOLIDARITY, to investigate whether this dangerous respiratory" exact="disease" post="could be treated with the available therapeutic aids (https://news.un.org/en/story/2020/03/1059722)."/>
  <result pre="anti-HIV activity through post-transcriptional inhibition of gp120 present on the" exact="viral" post="envelope or inhibition of Tat-mediated transactivation (Jiang et al.1996;"/>
  <result pre="the host cell, it is more likely that chloroquine stops" exact="viral" post="spread by blocking the process of uncoating and release"/>
  <result pre="current data from various small and non-randomized trials show only" exact="limited" post="effects of CQ/HCQ or HCQ-azithromycin combination on treatment for"/>
  <result pre="A JAK inhibitor that may interfere with the inflammatory processes" exact="Rheumatoid arthritis" post="Â 206361-99-1 Darunavir Aspartyl protease inhibitor Interface with viral"/>
  <result pre="JAK inhibitor that may interfere with the inflammatory processes Rheumatoid" exact="arthritis" post="Â 206361-99-1 Darunavir Aspartyl protease inhibitor Interface with viral"/>
  <result pre="Rheumatoid arthritis Â 206361-99-1 Darunavir Aspartyl protease inhibitor Interface with" exact="viral" post="replication Hepatitis C, Ebola virus, Marburg virus Â 36791-04-5"/>
  <result pre="Â 206361-99-1 Darunavir Aspartyl protease inhibitor Interface with viral replication" exact="Hepatitis" post="C, Ebola virus, Marburg virus Â 36791-04-5 Ribavirin Inosine"/>
  <result pre="dehydrogenase Inhibition of Inosine monophosphate dehydrogenase(induction of mutagenesis) RSV infection," exact="hepatitis C," post="some viral hemogrrhagic fevers Â 259793-96-9 Favipiravir RdRp A"/>
  <result pre="Inosine monophosphate dehydrogenase(induction of mutagenesis) RSV infection, hepatitis C, some" exact="viral" post="hemogrrhagic fevers Â 259793-96-9 Favipiravir RdRp A puirne nucleoside"/>
  <result pre="nucleoside that acts as an alternative substrate leading to inaccurate" exact="viral" post="RNA synthesis Viral infections Â 131707-23-8 Arbidol S protein/ACE2"/>
  <result pre="as an alternative substrate leading to inaccurate viral RNA synthesis" exact="Viral" post="infections Â 131707-23-8 Arbidol S protein/ACE2 An inhibitor that"/>
  <result pre="an alternative substrate leading to inaccurate viral RNA synthesis Viral" exact="infections" post="Â 131707-23-8 Arbidol S protein/ACE2 An inhibitor that may"/>
  <result pre="S protein/ACE2 An inhibitor that may disrupt that binding of" exact="viral" post="envelope protein to host cells and prevent viral entry"/>
  <result pre="binding of viral envelope protein to host cells and prevent" exact="viral" post="entry to the target cell Influenza anti viral Â"/>
  <result pre="and prevent viral entry to the target cell Influenza anti" exact="viral" post="Â 55981-09-4 Nitazoxanide Oxidative phosphorylation in mitochondria A drug"/>
  <result pre="Nitazoxanide Oxidative phosphorylation in mitochondria A drug that may inhibit" exact="viral" post="protein expression Various helminthic, protozoal, and viral infection-caused diarrhoea"/>
  <result pre="that may inhibit viral protein expression Various helminthic, protozoal, and" exact="viral" post="infection-caused diarrhoea B Â 54-05-7 Â 118-42-3 Chloroquine Hydroxchloroquine"/>
  <result pre="elevate endosomal pH and interfere with ACE2 glycosylation Material parasite" exact="infection" post="Â 192725-17-0 Â 155213-67-3 Lopinavir Ritonavir 3CLpro &amp;amp; PLpro-"/>
  <result pre="infection Â 192725-17-0 Â 155213-67-3 Lopinavir Ritonavir 3CLpro &amp;amp; PLpro-" exact="viral" post="proteases Protease inhibitors that may inhibit the viral protease:"/>
  <result pre="&amp;amp; PLpro- viral proteases Protease inhibitors that may inhibit the" exact="viral" post="protease: 3CLpro or PLpro Used in combination for HIV"/>
  <result pre="Act as nucleotide analogue A nucleotide analogue that may block" exact="viral" post="nucleotide synthesis to stop viral replication Ebola virus infection"/>
  <result pre="nucleotide analogue that may block viral nucleotide synthesis to stop" exact="viral" post="replication Ebola virus infection Â 145258-61-3 Interferon beta-1a (used"/>
  <result pre="may block viral nucleotide synthesis to stop viral replication Ebola" exact="virus infection" post="Â 145258-61-3 Interferon beta-1a (used in combination with Lopinavir"/>
  <result pre="block viral nucleotide synthesis to stop viral replication Ebola virus" exact="infection" post="Â 145258-61-3 Interferon beta-1a (used in combination with Lopinavir"/>
  <result pre="antigens and NK cells, activates different immunomodulators and antiviral proteins" exact="Multiple" post="sclerosis FigureÂ 1 Effects of repurposed drugs on different"/>
  <result pre="different pathways of SARS-CoV-2. Various drugs that were used to" exact="viral" post="infections like Ebola and HIV or antimalarial drugs like"/>
  <result pre="pathways of SARS-CoV-2. Various drugs that were used to viral" exact="infections" post="like Ebola and HIV or antimalarial drugs like chloroquine/hydroxychloroquine"/>
  <result pre="and animal models The development of a vaccine against a" exact="disease" post="is a combined effort from academicians and industries. Under"/>
  <result pre="vaccine potential by testing it in animal models for the" exact="disease" post="where the safety as well as immune responses to"/>
  <result pre="safety in Phase I and efficacy to protect against the" exact="disease" post="in Phases II and III, which take another 5â€&quot;10"/>
  <result pre="RNA, (ii) weakened virus known as VLPs, and (iii) targeting" exact="viral" post="proteins such as S protein (WHO 2020b). One of"/>
  <result pre="disease, duration of induced protection, the host immune response to" exact="infection" post="and vaccination (Griffin 2002). Thus, testing in animals is"/>
  <result pre="efforts against COVID-19 is that the most of the animal" exact="disease" post="models for SARS-CoV-2 are under testing and, in the"/>
  <result pre="disease models for SARS-CoV-2 are under testing and, in the" exact="absence of" post="these models, it is difficult to predict the outcome"/>
  <result pre="models that are being tested based on their pathogenesis after" exact="infection" post="with SARS-CoV-2. Rhesus macaques As the key 12 amino"/>
  <result pre="with macaques have shown that they do get infected with" exact="pulmonary" post="infiltrates as observed in radiographs, with high viral loads"/>
  <result pre="infected with pulmonary infiltrates as observed in radiographs, with high" exact="viral" post="loads in swabs of nose and throat and shedding"/>
  <result pre="in swabs of nose and throat and shedding in the" exact="upper" post="and lower respiratory tract (Munster et al.2020; Rockx et"/>
  <result pre="of nose and throat and shedding in the upper and" exact="lower" post="respiratory tract (Munster et al.2020; Rockx et al.2020). Taken"/>
  <result pre="nose and throat and shedding in the upper and lower" exact="respiratory" post="tract (Munster et al.2020; Rockx et al.2020). Taken together,"/>
  <result pre="tract (Munster et al.2020; Rockx et al.2020). Taken together, the" exact="disease" post="symptoms in rhesus macaques matches with the milder symptoms"/>
  <result pre="in rhesus macaques matches with the milder symptoms of SARS-CoV-2" exact="infection" post="in humans. Further, serum analysis demonstrate an increase in"/>
  <result pre="is also observed in macaques that older ones show higher" exact="viral" post="loads in nose and throat along with prolonged viral"/>
  <result pre="higher viral loads in nose and throat along with prolonged" exact="viral" post="shedding in the upper respiratory tract of old animals"/>
  <result pre="nose and throat along with prolonged viral shedding in the" exact="upper" post="respiratory tract of old animals (Rockx et al. 2020)."/>
  <result pre="and throat along with prolonged viral shedding in the upper" exact="respiratory" post="tract of old animals (Rockx et al. 2020). Thus,"/>
  <result pre="are model organisms for influenza virus and have similar lung" exact="morphology" post="as humans and can actually cough and sneeze, supporting"/>
  <result pre="ferrets, laboratory-bred mice always remain a convenient choice as a" exact="disease" post="model. However, coronavirus do not infect mice and rats"/>
  <result pre="ACE2 mice are successfully infected by SARS and develop lethal" exact="brain disease," post="making it an obvious choice to test infection with"/>
  <result pre="lethal brain disease, making it an obvious choice to test" exact="infection" post="with SARS-CoV-2 as well. However, due to lack of"/>
  <result pre="from China have shown that hACE2 mice do support SARS-CoV-2" exact="infection" post="where they reduce weight by 20% and virus replication"/>
  <result pre="in lungs. Moreover, infected hACE2 mice also suffer from interstitial" exact="pneumonia" post="where bronchioles are filled with periodic acid Schiff (PAS),"/>
  <result pre="also suffer from interstitial pneumonia where bronchioles are filled with" exact="periodic" post="acid Schiff (PAS), positive exudation or detached bronchial epithelium,"/>
  <result pre="and fulfill Kochâ€™s postulates, indicating that these mice are successful" exact="disease" post="model for SARS-CoV-2 (Bao et al.2020). Syrian hamster These"/>
  <result pre="SARS-CoV-2 (Bao et al.2020). Syrian hamster These animals support SARS" exact="infection" post="and show maximum similarity to human ACE2, where only"/>
  <result pre="ACE2, making them a testable model for SARS-CoV-2 infection. Upon" exact="infection" post="of SARS-CoV-2, Syrian hamsters demonstrate weight loss by ~11%"/>
  <result pre="Syrian hamsters demonstrate weight loss by ~11% along with high" exact="viral" post="load in nasal turbinate, lungs, and trachea. Further, the"/>
  <result pre="trachea. Further, the lethality rate in hamsters is 5% and" exact="exudative" post="inflammation with hemorrhage and necrosis of alveolae damage is"/>
  <result pre="the lethality rate in hamsters is 5% and exudative inflammation" exact="with hemorrhage" post="and necrosis of alveolae damage is visible during the"/>
  <result pre="and necrosis of alveolae damage is visible during the initial" exact="infection" post="period. The inflammation of intestinal mucosal epithelium that is"/>
  <result pre="epithelium that is the causative agent of diarrohea along with" exact="myocardial degeneration" post="is consistent with the pathogenesis observed in humans. Importantly,"/>
  <result pre="induced at day 2 post-infection followed by the decrease of" exact="type II" post="interferon and IL6 and increase of TGF-Î² at day"/>
  <result pre="Consistent with this, Syrian hamsters are able to transmit the" exact="disease" post="to naÃ¯ve hamsters upon challenge with SARS-CoV-2 (Chan et"/>
  <result pre="an appropriate model for COVID-19. In order to fight coronavirus" exact="infection" post="and win the race against time, Moderna, a biotechnological"/>
  <result pre="biotechnological company in collaboration with National Institute of Allergy and" exact="Infectious" post="Disease (NIAID), USA, has already begun Phase I clinical"/>
  <result pre="company in collaboration with National Institute of Allergy and Infectious" exact="Disease" post="(NIAID), USA, has already begun Phase I clinical trial"/>
  <result pre="antibody response after immunization in mice and a lack of" exact="disease" post="model for coronavirus. CanSino Biologics from China has also"/>
  <result pre="In the history of mankind, it has been clear that" exact="viral" post="pandemics have been common in affecting millions of people."/>
  <result pre="control viruses, extreme steps are often needed. Therefore, in the" exact="absence of" post="disease model, backed by their antibody responses in mice,"/>
  <result pre="extreme steps are often needed. Therefore, in the absence of" exact="disease" post="model, backed by their antibody responses in mice, NIAID"/>
  <result pre="of ganciclovir. Although ganciclovir is successful in treating patients with" exact="acquired" post="immunodeficiency syndrome-related cytomegalovirus retinitis, due to lack of animal"/>
  <result pre="ganciclovir. Although ganciclovir is successful in treating patients with acquired" exact="immunodeficiency" post="syndrome-related cytomegalovirus retinitis, due to lack of animal studies,"/>
  <result pre="dosages in Great Britain. In another instance, to treat human" exact="autoimmune disease," post="a monoclonal antibody TGN1412, after going through animal models,"/>
  <result pre="volunteers (Van Norman 2019). However, TGN1412 is now restored for" exact="rheumatoid arthritis" post="after developing better assays for studying immune responses and"/>
  <result pre="(Van Norman 2019). However, TGN1412 is now restored for rheumatoid" exact="arthritis" post="after developing better assays for studying immune responses and"/>
  <result pre="share a lot of genomic similarities; the final response to" exact="disease" post="will also depend on the epigenome and environmental differences."/>
  <result pre="not possible to perform safety and challenge studies for a" exact="disease" post="in humans. Also, animal studies provide the foundation to"/>
  <result pre="disease. Further, it is difficult to study the progression of" exact="disease" post="in humans but it is easy in an animal"/>
  <result pre="Although cell lines can also be used to study the" exact="infection" post="process, animal models provide the advantage of studying the"/>
  <result pre="infection process, animal models provide the advantage of studying the" exact="viral" post="multiplication with respect to symptoms and physiology of an"/>
  <result pre="in an organism. Another problem faced by vaccine efforts against" exact="viral" post="diseases, especially viruses having RNA as the genetic material,"/>
  <result pre="models is that it has been observed in case of" exact="viral" post="infections that sometimes the administration of vaccines enhances the"/>
  <result pre="is that it has been observed in case of viral" exact="infections" post="that sometimes the administration of vaccines enhances the susceptibility"/>
  <result pre="or antigen sin and is common for vaccine candidates of" exact="HIV/AIDS" post="virus and Dengue virus. Once the subject is immunized"/>
  <result pre="and is common for vaccine candidates of HIV/AIDS virus and" exact="Dengue" post="virus. Once the subject is immunized with the antigen,"/>
  <result pre="to FcÎ³ receptor on circulating monocytes, resulting in the efficient" exact="infection" post="of monocytes by the virus (Halstead 2002). Thus, instead"/>
  <result pre="higher complications and death of the subject in case of" exact="infection" post="by the pathogen (Huisman et al.2009). Therefore, the biotech"/>
  <result pre="are low. However, challenge of these cats results in enhanced" exact="susceptibility to" post="infection along with death of cats (Huisman et al.2009)."/>
  <result pre="However, challenge of these cats results in enhanced susceptibility to" exact="infection" post="along with death of cats (Huisman et al.2009). This"/>
  <result pre="success, effective and targeted drugs and vaccines for the SARS-CoV-2" exact="infection" post="are still awaited. Moreover, agencies like WHO and FDA"/>
  <result pre="of the drug/vaccine could have devastating consequences. Abbreviations COVID-19 coronavirus" exact="disease" post="2019 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 MERS"/>
  <result pre="have devastating consequences. Abbreviations COVID-19 coronavirus disease 2019 SARS-CoV-2 severe" exact="acute" post="respiratory syndrome coronavirus 2 MERS Middle East respiratory syndrome"/>
  <result pre="devastating consequences. Abbreviations COVID-19 coronavirus disease 2019 SARS-CoV-2 severe acute" exact="respiratory" post="syndrome coronavirus 2 MERS Middle East respiratory syndrome ACE2"/>
  <result pre="consequences. Abbreviations COVID-19 coronavirus disease 2019 SARS-CoV-2 severe acute respiratory" exact="syndrome" post="coronavirus 2 MERS Middle East respiratory syndrome ACE2 angiotensin-converting"/>
  <result pre="SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 MERS Middle East" exact="respiratory" post="syndrome ACE2 angiotensin-converting enzyme 2 HA hemagglutinin WHO World"/>
  <result pre="severe acute respiratory syndrome coronavirus 2 MERS Middle East respiratory" exact="syndrome" post="ACE2 angiotensin-converting enzyme 2 HA hemagglutinin WHO World Health"/>
  <result pre="Food And Drug Administration NIAID National Institute of Allergy and" exact="Infectious" post="Disease MCP1 monocyte chemoattractant protein 1 HIV Human immunodeficienty"/>
  <result pre="And Drug Administration NIAID National Institute of Allergy and Infectious" exact="Disease" post="MCP1 monocyte chemoattractant protein 1 HIV Human immunodeficienty virus"/>
  <result pre="Administration NIAID National Institute of Allergy and Infectious Disease MCP1" exact="monocyte" post="chemoattractant protein 1 HIV Human immunodeficienty virus AIDS accquired"/>
  <result pre="monocyte chemoattractant protein 1 HIV Human immunodeficienty virus AIDS accquired" exact="immunodeficiency" post="syndrome This article is part of the Topical Collection:"/>
  <result pre="chemoattractant protein 1 HIV Human immunodeficienty virus AIDS accquired immunodeficiency" exact="syndrome" post="This article is part of the Topical Collection: COVID-19:"/>
  <result pre="syndrome This article is part of the Topical Collection: COVID-19:" exact="Disease" post="Biology &amp;amp; Intervention. Corresponding editor: Dipankar Nandi These authors"/>
  <result pre="to study coronavirus in transgenic animals - some are in" exact="short" post="supplyNature202057918310.1038/d41586-020-00698-x CameronMJKelvinAALeonAJCameronCMRanLXuLChuYDaneshAet al.Lack of innate interferon responses during SARS"/>
  <result pre="supplyNature202057918310.1038/d41586-020-00698-x CameronMJKelvinAALeonAJCameronCMRanLXuLChuYDaneshAet al.Lack of innate interferon responses during SARS coronavirus" exact="infection" post="in a vaccination and reinfection ferret modelPLoS One201210.1371/journal.pone.0045842 CaoBWangYWenDLiuWWangJFanGRuanLSongBet"/>
  <result pre="2020 Simulation of the clinical and pathological manifestations of Coronavirus" exact="Disease" post="2019 (COVID-19) in golden Syrian hamster model: implications for"/>
  <result pre="Disease 2019 (COVID-19) in golden Syrian hamster model: implications for" exact="disease" post="pathogenesis and transmissibility. Clin. Infect. Dis. 10.1093/cid/ciaa325 ColsonPRolainJ-MLagierJ-CBrouquiPRaoultDChloroquine and"/>
  <result pre="weapons to fight COVID-192020IntJ. Antimicrob. Agents EnkirchTvon MesslingVFerret models of" exact="viral" post="pathogenesisVirology2015479â€&quot;48025927010.1016/j.virol.2015.03.017 GralinskiLEMenacheryVDReturn of the coronavirus: 2019-nCoVViruses20201213510.3390/v12020135 GriffinJFTA strategic approach"/>
  <result pre="formulation and deliveryAdv. Drug Del. Rev.20025485186110.1016/S0169-409X(02)00072-8 HalsteadSBDengue hemorrhagic fever: two" exact="infections" post="and antibody dependent enhancement, a brief history and personal"/>
  <result pre="New Zealand white rabbits when MERS-CoV reinfection occurs in the" exact="absence of" post="neutralizing antibodyPLoS Pathog.201713e100656510.1371/journal.ppat.100656528817732 HuismanWMartinaBEERimmelzwaanGFGrutersRAOsterhausADMEVaccine-induced enhancement of viral infectionsVaccine20092750551210.1016/j.vaccine.2008.10.08719022319 JiangMCLinJKChenSSInhibition"/>
  <result pre="in the absence of neutralizing antibodyPLoS Pathog.201713e100656510.1371/journal.ppat.100656528817732 HuismanWMartinaBEERimmelzwaanGFGrutersRAOsterhausADMEVaccine-induced enhancement of" exact="viral" post="infectionsVaccine20092750551210.1016/j.vaccine.2008.10.08719022319 JiangMCLinJKChenSSInhibition of HIV-1 Tat-mediated transactivation by quinacrine and"/>
  <result pre="transmission of SARS-CoV-2 in ferretsCell Host Microbe202010.1016/j.chom.2020.03.023 LaiCCLiuYHWangCYWangYHHsuehSCYenMYKoWCHsuehPRAsymptomatic carrier state," exact="acute" post="respiratory disease, and pneumonia due to severe acute respiratory"/>
  <result pre="of SARS-CoV-2 in ferretsCell Host Microbe202010.1016/j.chom.2020.03.023 LaiCCLiuYHWangCYWangYHHsuehSCYenMYKoWCHsuehPRAsymptomatic carrier state, acute" exact="respiratory" post="disease, and pneumonia due to severe acute respiratory syndrome"/>
  <result pre="ferretsCell Host Microbe202010.1016/j.chom.2020.03.023 LaiCCLiuYHWangCYWangYHHsuehSCYenMYKoWCHsuehPRAsymptomatic carrier state, acute respiratory disease, and" exact="pneumonia" post="due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2):"/>
  <result pre="carrier state, acute respiratory disease, and pneumonia due to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ. Microbiol."/>
  <result pre="state, acute respiratory disease, and pneumonia due to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ. Microbiol. Immunol."/>
  <result pre="acute respiratory disease, and pneumonia due to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2): Facts and mythsJ. Microbiol. Immunol. Infect.202010.1016/j.jmii.2020.02.012"/>
  <result pre="(SARS-CoV-2): Facts and mythsJ. Microbiol. Immunol. Infect.202010.1016/j.jmii.2020.02.012 LiangKMathematical model of" exact="infection" post="kinetics and its analysis for COVID-19SARS and MERS. Infect."/>
  <result pre="H, Nishiura K, et al. 2019 Antiâ€&quot;spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARS-CoV"/>
  <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARS-CoV infection. JCI Insight. 410.1172/jci.insight.123158 LuRZhaoXLiJNiuPYangBWuHWangWSongHet al.Genomic characterisation and"/>
  <result pre="al.Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusionAutophagy2018141435145510.1080/15548627.2018.147431429940786 McCrayPBPeweLWohlford-LenaneCHickeyMManzelLShiLNetlandJJiaHPet al.Lethal" exact="infection" post="of K18-hACE2 mice infected with severe acute respiratory syndrome"/>
  <result pre="fusionAutophagy2018141435145510.1080/15548627.2018.147431429940786 McCrayPBPeweLWohlford-LenaneCHickeyMManzelLShiLNetlandJJiaHPet al.Lethal infection of K18-hACE2 mice infected with severe" exact="acute" post="respiratory syndrome coronavirusJ. Virol.20078181382110.1128/JVI.02012-0617079315 Melin AD, Janiak MC, Marrone"/>
  <result pre="McCrayPBPeweLWohlford-LenaneCHickeyMManzelLShiLNetlandJJiaHPet al.Lethal infection of K18-hACE2 mice infected with severe acute" exact="respiratory" post="syndrome coronavirusJ. Virol.20078181382110.1128/JVI.02012-0617079315 Melin AD, Janiak MC, Marrone F,"/>
  <result pre="al.Lethal infection of K18-hACE2 mice infected with severe acute respiratory" exact="syndrome" post="coronavirusJ. Virol.20078181382110.1128/JVI.02012-0617079315 Melin AD, Janiak MC, Marrone F, Arora"/>
  <result pre="L, Schulz J, Meade-white K, Okumura A, et al. 2020" exact="Respiratory" post="disease and virus shedding in rhesus macaques inoculated with"/>
  <result pre="Schulz J, Meade-white K, Okumura A, et al. 2020 Respiratory" exact="disease" post="and virus shedding in rhesus macaques inoculated with SARS-CoV-2."/>
  <result pre="approach? JACC: Basic Transl Sci. 4 845â€&quot;854 WHO 2020a Coronavirus" exact="disease" post="(COVID-19) situation report-106. who.int. 5 May 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200505covid-19-sitrep-106.pdf?sfvrsn=47090f63_2 WHO"/>
 </snippets>
</snippetsTree>
